Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

asciminib

Novartis building

NICE turns down Novartis’ blood cancer drug Jakavi

Uncertainties remain about drug’s cost-effectiveness, according to final draft guidance

Novartis day

Xolair gets asthma green light from NICE

Final guidance recommends Novartis drug for severe persistent asthma 

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

Roche faces another NICE rejection for Avastin

Draft guidance turns down drug for use in ovarian cancer

- PMLiVE

US-based Millennium launches blood cancer website

The Takeda Oncology Company roll out new multiple myeloma website

- PMLiVE

Alkermes cuts jobs in Ireland as Novartis invests

130 jobs to go at manufacturing facility in Athlone as Novartis creates 100 roles in Dublin

- PMLiVE

Roche launches test for thyroid cancer

Elecsys Calcitonin to support diagnosis of relapse following surgery

- PMLiVE

Charity says patients worried about Cancer Drugs Fund’s future

Beating Bowel Cancer demands clarity from DH about future for access to cancer medicines in England

- PMLiVE

Novartis says Indian Glivec verdict “discourages innovation”

Country's Supreme Court denies the cancer drug patent protection

Novartis building

Pharma waits for Glivec patent verdict in India

Intellectual property decision could have far-reaching consequences for industry

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links